Abstract
Introduction: The aim of the study was to assess the strength of the online tool RiskCheck Bladder Cancer©, version 5.0 (RCBC) for early detection of bladder cancer (BC). Materials and Methods: RCBC was evaluated retrospectively based on the data of 241 patients, of which 141 were suffering from BC. Statistical analysis was performed by descriptive statistics, nonparametric group comparison, classification tree analysis and ROC analysis. Results: ROC analysis of the risk classification showed a sensitivity of 71.6%, a specificity of 56.5%, a positive predictive value of 67.8%, a negative predictive value of 52% and an accuracy of 63.5%. BC risk factors ranked by importance are time of smoking (p < 0.0001), gender (within the nonsmoking group: p < 0.009), occupational toxin exposure (within the group <35 years of smoking: p < 0.048) and amount of consumed cigarettes resulting in a 95% association with BC (within the group >35 years of smoking: p < 0.0001). Conclusions: The high predictive power of RCBC for the identification of asymptomatic patients living under risk could be demonstrated.
References
1.
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J: EAU guidelines on non-muscle-carcinoma of the bladder. Actas Urol Esp 2009;33:361-371.
2.
Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA: Update of the clinical guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma. Actas Urol Esp 2010;34:51-62.
3.
Shapur N, Pode D, Katz R, Shapiro A, Yutkin V, Pizov G, Appelbaum L, Zorn KC, Duvdevani M, Landau EH, Gofrit ON: Predicting the risk of high-grade bladder cancer using noninvasive data. Urol Int 2011;87:319-324.
4.
Altieri VM, Castellucci R, Palumbo P, Verratti V, Sut M, Olivieri R, Manco R, Ricciardulli S, Nicolai M, Criniti P, Tenaglia RL: Recurrence and progression in non-muscle-invasive bladder cancer using eortc risk tables. Urol Int 2012;89:61-66.
5.
RKI GdeKiDeVud (ed): Krebs in Deutschland. Saarbrücken, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. und das RKI, 2006.
6.
Brandenburg TL (ed): Qualitätsbericht 2009 - Qualitätssicherung durch klinische Krebsregister, ed 10. Cottbus, Tumorzentrum Land Brandenburg, 2009, vol 10.
7.
Fischer CG, Waechter W, Kraus S, Fuentecilla Perez E, Weidner W, Dudeck J: Urologic tumors in the Federal Republic of Germany: data on 56,013 cases from hospital cancer registries. Cancer 1998;82:775-783.
8.
Lüdecke G, Weidner W: Risikocheck©, an internet-based instrument to identify risk populations for bladder cancer. Experiences of two years online risk check in for languages: EAU. Paris, European Urology, 2006.
9.
Lotan Y, Elias K, Svatek RS, Bagrodia A, Nuss G, Moran B, Sagalowsky AI: Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol 2009;182:52-57.
10.
Steiner H, Bergmeister M, Verdorfer I, Granig T, Mikuz G, Bartsch G, Stoehr B, Brunner A: Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int 2008;102:291-296.
11.
Vercelli M, Quaglia A, Parodi S, Crosignani P: Cancer prevalence in the elderly. Itapreval working group. Tumori 1999;85:391-399.
12.
Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH: The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 2010;105:300-308.
13.
Bermejo JL, Sundquist J, Hemminki K: Sex-specific familial risks of urinary bladder cancer and associated neoplasms in Sweden. Int J Cancer 2009;124:2166-2171.
14.
Mommsen S, Aagaard J: Tobacco as a risk factor in bladder cancer. Carcinogenesis 1983;4:335-338.
15.
McCormack V, Agudo A, Dahm C, Overvad K, Olsen A, Tjonneland A, Kaaks R, Boeing H, Manjer J, Almquist M, Hallmans G, Johansson I, Chirlaque M, Barricarte A, Dorronsoro M, Rodriguez L, Redondo M, Khaw K, Wareham N, Allen N, Key T, Riboli E, Boffetta P: Cigar and pipe smoking and cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010;127:2402-2411.
16.
Pohlabeln H, Jockel KH, Bolm-Audorff U: Non-occupational risk factors for cancer of the lower urinary tract in Germany. Eur J Epidemiol 1999;15:411-419.
17.
Vineis P: Bladder cancer risk in painters. Occup Environ Med 2010;67:505-506.
18.
Harling M, Schablon A, Schedlbauer G, Dulon M, Nienhaus A: Bladder cancer among hairdressers: a meta-analysis. Occup Environ Med 2010;67:351-358.
19.
Pira E, Piolatto G, Negri E, Romano C, Boffetta P, Lipworth L, McLaughlin JK, La Vecchia C: Bladder cancer mortality of workers exposed to aromatic amines: a 58-year follow-up. J Natl Cancer Inst 2010;102:1096-1099.
20.
Behrens T, Schill W, Ahrens W: Elevated cancer mortality in a german cohort of bitumen workers: extended follow-up through 2004. J Occup Environ Hyg 2009;6:555-561.
21.
Friesen MC, Costello S, Eisen EA: Quantitative exposure to metalworking fluids and bladder cancer incidence in a cohort of autoworkers. Am J Epidemiol 2009;169:1471-1478.
22.
Kang D, Davis LK, Hunt P, Kriebel D: Cancer incidence among male Massachusetts firefighters, 1987-2003. Am J Ind Med 2008;51:329-335.
23.
Nieder AM, Porter MP, Soloway MS: Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol 2008;180:2005-2009.
24.
Sandhu JS, Vickers AJ, Bochner B, Donat SM, Herr HW, Dalbagni G: Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. BJU Int 2006;98:59-62.
25.
Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, Lopez-Abente G, Tzonou A, Chang-Claude J, Bolm-Audorff U, Jockel KH, Donato F, Serra C, Wahrendorf J, Hours M, T'Mannetje A, Kogevinas M, Boffetta P: Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 2000;86:289-294.
26.
Golka K, Weistenhofer W: Fire fighters, combustion products, and urothelial cancer. J Toxicol Environ Health B Crit Rev 2008;11:32-44.
27.
Gibbs GW, Armstrong B, Sevigny M: Mortality and cancer experience of quebec aluminum reduction plant workers. 2. Mortality of three cohorts hired on or before January 1, 1951. J Occup Environ Med 2007;49:1105-1123.
28.
Koutros S, Lynch CF, Ma X, Lee WJ, Hoppin JA, Christensen CH, Andreotti G, Freeman LB, Rusiecki JA, Hou L, Sandler DP, Alavanja MC: Heterocyclic aromatic amine pesticide use and human cancer risk: results from the US Agricultural health study. Int J Cancer 2009;124:1206-1212.
29.
Monach PA, Arnold LM, Merkel PA: Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum 2010;62:9-21.
30.
Kalisvaart JF, Katsumi HK, Ronningen LD, Hovey RM: Bladder cancer in spinal cord injury patients. Spinal Cord 2010;48:257-261.
31.
Tchounwou PB, Patlolla AK, Centeno JA: Carcinogenic and systemic health effects associated with arsenic exposure - a critical review. Toxicol Pathol 2003;31:575-588.
32.
Khaled H, El Hattab O, Moneim DA, Kassem HA, Morsi A, Sherif G, Darwish T, Gaafar R: A prognostic index (bladder prognostic index) for bilharzial-related invasive bladder cancer. Urol Oncol 2005;23:254-260.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
